Table 1.
Baseline characteristics of patients enrolled
| Characteristic | Overall (n = 326) | 2 mg* (n = 276) | 4 mg* (n = 43) | |
|---|---|---|---|---|
| Sex | Male | 324 (99.4) | 274 (99.3) | 43 (100.0) |
| Female | 2 (0.6) | 2 (0.7) | 0 (0.0) | |
| Age (year) | Mean ± SD | 53.9 ± 10.5 | 54.2 ± 10.4 | 51.3 ± 10.5 |
| Height (cm) | Mean ± SD | 170.18 ± 6.05 | 170.07 ± 6.02 | 170.86 ± 6.08 |
| Weight (kg) | Mean ± SD | 76.77 ± 12.37 | 76.01 ± 11.90 | 82.17 ± 14.12 |
| Serum uric acid level (mg/dL) | Mean ± SD | 8.79 ± 1.13 | 8.63 ± 1.03 | 9.76 ± 1.25 |
|
eGFR (mL/min/1.73 m2) |
Mean ± SD | 69.6 ± 13.2 | 69.7 ± 12.7 | 70.0 ± 15.7 |
| HOMA-IR | Mean ± SD | 1.77 ± 1.59 | 1.69 ± 1.39 | 2.32 ± 2.49 |
| Medical history (hyperuricemia) | No | 180 (55.2) | 156 (56.5) | 21 (48.8) |
| Yes | 146 (44.8) | 120 (43.5) | 22 (51.2) | |
| History of gouty arthritis | No | 55 (16.9) | 49 (17.8) | 6 (14.0) |
| Yes | 271 (83.1) | 227 (82.2) | 37 (86.0) | |
| Gouty tophus | No | 320 (98.2) | 272 (98.6) | 42 (97.7) |
| Yes | 6 (1.8) | 4 (1.4) | 1 (2.3) | |
| Comorbidity** | No | 42 (12.9) | 38 (13.8) | 3 (7.0) |
| Yes | 284 (87.1) | 238 (86.2) | 40 (93.0) | |
| Concomitant drugs** | No | 122 (37.4) | 103 (37.3) | 17 (39.5) |
| Yes | 204 (62.6) | 173 (62.7) | 26 (60.5) | |
| Drinking habit | No | 156 (47.9) | 135 (48.9) | 19 (44.2) |
| Yes | 170 (52.1) | 141 (51.1) | 24 (55.8) | |
| History of urinary calculus | No | 291 (89.3) | 248 (89.9) | 41 (95.3) |
| Yes | 35 (10.7) | 28 (10.1) | 2 (4.7) | |
| Type of hyperuricemia | Underexcretion type | 279 (85.6) | 237 (85.9) | 36 (83.7) |
| Combined or normal type | 47 (14.4) | 39 (14.1) | 7 (16.3) |
Counting value/nominal scale is expressed as n (%)
eGFR estimated glomerular filtration rate, HOMA-IR homeostatic model assessment for insulin resistance
*Dose at completion of treatment (excluding patients who withdrew at a dose of 0.5 or 1 mg)
**The main comorbidities were hypertension, dyslipidemia, and diabetes, and concomitant drugs were antihypertensives, vasodilators, and dyslipidemia